Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
How reliable is the liquid biopsy on patients with progressing HER2 positive breast cancer with negative HER2 on liquid testing?
How does this change your treatment decisions?
Related Questions
Is there any data to use PIK3CA directed agents in mutated metastatic triple negative breast cancer?
How, if at all, do you use changes in SUV on a PET-CT to assess for disease progression/response in patients with metastatic breast cancer?
In patients with both ESR1 and PIK3CA mutations who have progressed on AI+CDK4/6 inhibitor, how are you deciding the treatment/sequence of next-line therapies?
What strategies do you implement to control the nausea from Enhertu?
Do you offer hormonal therapy in combination with an anti-HER2 T-DM1 or T-DXd in metastatic ER+ HER2+ breast cancer?
What is your experience and treatment efficacy of tucatinib if used after enhertu in metastatic breast cancer?
Do you switch therapy to sacituzumab in a patient with metastatic HR+ HER2- breast cancer who has stable systemic disease but new <1cm brain metastasis?
How do you treat front line de novo HER2 positive metastatic breast cancer with brain metastases?
How do you treat metastatic adenoid cystic carcinoma of breast primary, ER 3%, PR, HER 2 negative with liver only metastasis?
Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?